MX2024011449A - Composiciones protésicas de canales iónicos que comprenden cristales de anfotericina b recubiertos con lípidos - Google Patents
Composiciones protésicas de canales iónicos que comprenden cristales de anfotericina b recubiertos con lípidosInfo
- Publication number
- MX2024011449A MX2024011449A MX2024011449A MX2024011449A MX2024011449A MX 2024011449 A MX2024011449 A MX 2024011449A MX 2024011449 A MX2024011449 A MX 2024011449A MX 2024011449 A MX2024011449 A MX 2024011449A MX 2024011449 A MX2024011449 A MX 2024011449A
- Authority
- MX
- Mexico
- Prior art keywords
- prosthetic
- lipid
- crystals
- ion channel
- increasing
- Prior art date
Links
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 title abstract 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 title abstract 2
- 229960003942 amphotericin b Drugs 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263321965P | 2022-03-21 | 2022-03-21 | |
| PCT/US2023/015762 WO2023183297A1 (en) | 2022-03-21 | 2023-03-21 | Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011449A true MX2024011449A (es) | 2024-12-06 |
Family
ID=88101847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011449A MX2024011449A (es) | 2022-03-21 | 2024-09-18 | Composiciones protésicas de canales iónicos que comprenden cristales de anfotericina b recubiertos con lípidos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12419899B2 (enExample) |
| EP (1) | EP4496588A4 (enExample) |
| JP (1) | JP2025510096A (enExample) |
| KR (1) | KR20240164801A (enExample) |
| CN (1) | CN119365218A (enExample) |
| AU (1) | AU2023238751A1 (enExample) |
| CA (1) | CA3250825A1 (enExample) |
| CL (1) | CL2024002812A1 (enExample) |
| CO (1) | CO2024013912A2 (enExample) |
| IL (1) | IL315719A (enExample) |
| MX (1) | MX2024011449A (enExample) |
| WO (1) | WO2023183297A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
| WO2025064626A1 (en) * | 2023-09-20 | 2025-03-27 | The Board Of Trustees Of The University Of Illinois | Additive effects for molecular prosthetcs and cftr modulators in cf epithelia |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| CA2194049A1 (en) | 1994-06-28 | 1996-01-11 | Georgi Stankov | Novel clinical uses of polyene macrolides |
| US6323191B1 (en) | 1998-06-19 | 2001-11-27 | Genzyme Corporation | Small molecule chloride transport |
| AUPQ066399A0 (en) | 1999-05-31 | 1999-06-24 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal combination use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US20040156792A1 (en) | 2002-12-31 | 2004-08-12 | Nektar Therapeutics | Pharmaceutical formulation with an insoluble active agent |
| PT1581236E (pt) | 2002-10-29 | 2013-12-24 | Insmed Inc | Libertação prolongada de anti-infecciosos |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| JP2006513235A (ja) | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 真菌感染症療法のためのエアゾール化可能な医薬製剤 |
| WO2004091572A2 (en) | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| TWI249408B (en) | 2003-12-10 | 2006-02-21 | Ind Tech Res Inst | New antifungal formulation and manufacturing method thereof |
| US7452524B2 (en) | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Method for improvement of tolerance for therapeutically effective agents delivered by inhalation |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| ATE476965T1 (de) | 2004-06-11 | 2010-08-15 | Verma Jitendra Nath | Sterol-angereicherte multilamellare amphotericin- enthaltende liposomen in kochsalzlösung und herstellungsverfahren |
| EP3067047B1 (en) * | 2005-12-08 | 2022-04-20 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| JP5457830B2 (ja) | 2006-04-03 | 2014-04-02 | オディディ，イサ | オルガノゾル被膜を含む制御放出送達デバイス |
| HUE031951T2 (en) | 2006-10-10 | 2017-08-28 | Jina Pharmaceuticals Inc | Aqueous systems for lipid-based drug compounds; preparations, processes and their use |
| WO2009006311A2 (en) * | 2007-06-29 | 2009-01-08 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| EP2488160B1 (en) | 2009-10-16 | 2020-07-01 | Lifecare Innovations Pvt. Ltd. | Liposomal amphotericin formulation comprising cholesterol for treating fungal infections |
| WO2011050311A1 (en) | 2009-10-22 | 2011-04-28 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Use of endostatin peptides for the treatment of fibrosis |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| US20150297725A1 (en) * | 2012-07-30 | 2015-10-22 | Rutgers, The State University Of New Jersey | Cochleates made with soy phosphatidylserine |
| KR102548341B1 (ko) | 2013-10-07 | 2023-06-26 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 개선된 치료 지수를 갖는 암포테리신 b 유도체 |
| JP6796581B2 (ja) | 2014-11-04 | 2020-12-09 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | ミッシングタンパク質の小分子模倣体を用いた生理機能の回復 |
| EP3439668B1 (en) | 2016-04-08 | 2024-06-19 | The Board of Trustees of the University of Illinois | Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia |
| EP3442512A4 (en) | 2016-04-15 | 2020-07-22 | The UAB Research Foundation | METHODS AND COMPOUNDS FOR STIMULATING THE TRANSLECTURE OF PREMATURE TERMINATION CODONS |
| FI3694526T3 (fi) * | 2017-10-11 | 2025-02-06 | Univ Illinois | Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten |
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
-
2023
- 2023-03-21 IL IL315719A patent/IL315719A/en unknown
- 2023-03-21 CA CA3250825A patent/CA3250825A1/en active Pending
- 2023-03-21 KR KR1020247034896A patent/KR20240164801A/ko active Pending
- 2023-03-21 EP EP23775542.6A patent/EP4496588A4/en active Pending
- 2023-03-21 WO PCT/US2023/015762 patent/WO2023183297A1/en not_active Ceased
- 2023-03-21 JP JP2024556375A patent/JP2025510096A/ja active Pending
- 2023-03-21 AU AU2023238751A patent/AU2023238751A1/en active Pending
- 2023-03-21 CN CN202380041480.3A patent/CN119365218A/zh active Pending
-
2024
- 2024-09-17 CL CL2024002812A patent/CL2024002812A1/es unknown
- 2024-09-18 MX MX2024011449A patent/MX2024011449A/es unknown
- 2024-09-20 US US18/891,739 patent/US12419899B2/en active Active
- 2024-10-16 CO CONC2024/0013912A patent/CO2024013912A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240164801A (ko) | 2024-11-20 |
| CN119365218A (zh) | 2025-01-24 |
| EP4496588A4 (en) | 2026-04-22 |
| AU2023238751A1 (en) | 2024-10-31 |
| WO2023183297A1 (en) | 2023-09-28 |
| CL2024002812A1 (es) | 2025-01-10 |
| US12419899B2 (en) | 2025-09-23 |
| IL315719A (en) | 2024-11-01 |
| CA3250825A1 (en) | 2023-09-28 |
| CO2024013912A2 (es) | 2025-01-13 |
| JP2025510096A (ja) | 2025-04-14 |
| US20250009776A1 (en) | 2025-01-09 |
| EP4496588A1 (en) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024011449A (es) | Composiciones protésicas de canales iónicos que comprenden cristales de anfotericina b recubiertos con lípidos | |
| Rubin | Mucolytics, expectorants, and mucokinetic medications | |
| Friedman et al. | Intranasal and transantral ethmoidectomy: a 20‐year experience | |
| DK0833643T3 (da) | Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme | |
| YU209288A (en) | Process for producing compound for treating, which contains azelastin for use in nose and/or eye | |
| BR0107858A (pt) | Implante de fusão espinhal | |
| BRPI0415858A (pt) | compostos de medicamentos terapêuticos modificados por tocoferol | |
| BR0000578A (pt) | Formulacao medicamentosa retardadora | |
| BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
| ATE250420T1 (de) | Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten | |
| CA2285203A1 (en) | Compositions containing capsaicin or capsaicin analogues and a local anesthetic | |
| NZ510887A (en) | Formulations of fexofenadine for ocular and nasal delivery | |
| NO20015931L (no) | Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin | |
| ES2098920T3 (es) | Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina. | |
| CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| BG104797A (en) | Use of dexmedetomi dine for sedative effect in patients in an intensive care unit | |
| DE69633279D1 (de) | Verfahren zur herstellung einer zusammensetzung enthaltend modifizierten tierlichen lungensurfactant | |
| PT973546E (pt) | Formulacoes estabilizadas de virus de papiloma humano | |
| SA03240393B1 (ar) | مضادات مستقبل 5-HT IB/Id لعلاج الصداع headache الناتج عن تناول مضاد مستقبل إندوثيلين endothelin receptor antagonist | |
| WO2001089494A8 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| ATE310509T1 (de) | Methode zur behandlung eines analgesiebedürftigen patienten | |
| UHDE | The problem of permeability and anesthesia of the tympanic membrane | |
| MY136382A (en) | Use of cholesterol-lowering agent | |
| GR3034211T3 (en) | Synthetic lung surfactant. | |
| Feng et al. | Therapeutic effects of eustachian tube surfactant in barotitis media in guinea pigs |